Download
00404_2024_Article_7692.pdf 928,15KB
WeightNameValue
1000 Titel
  • The impact of Germany’s human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances
1000 Autor/in
  1. Goodman, Elizabeth |
  2. Reuschenbach, Miriam |
  3. Viering, Tammo |
  4. Luzak, Agnes |
  5. Greiner, Wolfgang |
  6. hampl, monika |
  7. Jacob, Christian |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-04
1000 Erschienen in
1000 Quellenangabe
  • 310(5):2639-2646
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00404-024-07692-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485141/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Human papillomavirus (HPV) is the most common sexually transmitted infection, responsible for multiple HPV-related diseases, including almost all cervical cancers. The highly effective HPV vaccination has been recommended under the German HPV national immunization program (NIP) since 2007 and is reimbursed by health insurances. Vaccination uptake rates, however, remain suboptimal and data on the real-world impact of HPV vaccination in Germany are lacking. This study aims to demonstrate the population-level impact of Germany's NIP on HPV-related anogenital diseases among young women.!##!Methods!#!Retrospective claims data analysis using a classic impact study design comparing disease prevalence among 28- to 33-year-old women before and after introduction of the HPV-immunization program in Germany. Claims data representing approximately two thirds of German health insurances were used. HPV-related disease outcomes included cervical cancer and high grade precancers (cervical intraepithelial neoplasia (CIN) 2+), anogenital warts, as well as vulvar, vaginal, and anal precancer/cancer.!##!Results!#!Significant declines were seen for CIN2+, anogenital warts, and vaginal precancer/cancer. Prevalence of CIN2+ declined 51.1% from 0.92% (95% CI = 0.78%, 1.08%) to 0.45% (95% CI = 0.38%, 0.53%). There was a 38.6% decline in anogenital warts prevalence from 0.44% (95% CI = 0.36%, 0.54%) to 0.27% (95% CI = 0.22%, 0.32%) and 75.0% decline in vaginal precancer/cancer prevalence from 0.04% (95% CI = 0.02%, 0.07%) to 0.01% (95% CI = 0.00%, 0.02%).!##!Conclusion!#!The German HPV-immunization program has led to significant declines in female anogenital disease among young women in Germany, highlighting the importance of the vaccination. Moreover, the data suggest that increasing vaccination coverage in Germany could further strengthen the public-health impact of its HPV-immunization program.
1000 Sacherschließung
lokal Uterine Cervical Dysplasia/epidemiology [MeSH]
lokal Genital warts
lokal Germany
lokal Vaginal Neoplasms/epidemiology [MeSH]
lokal Condylomata Acuminata/epidemiology [MeSH]
lokal Anus Neoplasms/virology [MeSH]
lokal Germany/epidemiology [MeSH]
lokal Papillomavirus Vaccines/therapeutic use [MeSH]
lokal Claims data analysis
lokal Condylomata Acuminata/prevention
lokal Uterine Cervical Neoplasms/virology [MeSH]
lokal Cervical intraepithelial neoplasia (CIN)
lokal Prevalence [MeSH]
lokal Uterine Cervical Neoplasms/epidemiology [MeSH]
lokal Vaginal Neoplasms/prevention
lokal Immunization Programs/statistics
lokal Anus Neoplasms/epidemiology [MeSH]
lokal Female [MeSH]
lokal Insurance Claim Review [MeSH]
lokal Adult [MeSH]
lokal Papillomavirus Infections/prevention
lokal Uterine Cervical Neoplasms/prevention
lokal Humans [MeSH]
lokal Condylomata Acuminata/virology [MeSH]
lokal Retrospective Studies [MeSH]
lokal Papillomavirus Infections/epidemiology [MeSH]
lokal Uterine Cervical Dysplasia/prevention
lokal Papillomavirus Vaccines/administration
lokal Vaginal Neoplasms/virology [MeSH]
lokal Anus Neoplasms/prevention
lokal Human papillomavirus (HPV)
lokal Human Papillomavirus Viruses [MeSH]
lokal Uterine Cervical Dysplasia/virology [MeSH]
lokal Vaccination/statistics
lokal HPV vaccination
lokal Gynecologic Oncology
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9640-9884|https://orcid.org/0000-0003-4268-6250|https://orcid.org/0000-0003-4034-3297|https://frl.publisso.de/adhoc/uri/THV6YWssIEFnbmVz|https://orcid.org/0000-0001-9552-6969|https://orcid.org/0000-0002-5949-5891|https://orcid.org/0000-0001-6960-728X
1000 Hinweis
  • DeepGreen-ID: dd5f69b7886847dbbc9681c7b1acb713 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6516349.rdf
1000 Erstellt am 2025-07-04T21:08:09.001+0200
1000 Erstellt von 322
1000 beschreibt frl:6516349
1000 Zuletzt bearbeitet 2025-08-15T20:08:12.117+0200
1000 Objekt bearb. Fri Aug 15 20:08:12 CEST 2025
1000 Vgl. frl:6516349
1000 Oai Id
  1. oai:frl.publisso.de:frl:6516349 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source